ITGI wins $1m stent order for clinical trial
Hospitals in the company's own clinical trial will pay full price for the stents.
The trial is due to last three years, although preliminary results are expected in 2011 and further results in 2012. Good results from the trial could give ITGI's competitive position a strong boost. The company's Over-and-Under heterologous tissue covered stent already has EU CE Mark Certification, and the company has applied for US Food and Drug Administration (FDA) approval.
ITGI's share price rose 0.5% today to NIS 0.64, giving a market cap of NIS 41 million.
Published by Globes [online], Israel business news - www.globes-online.com - on February 18, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options